Literature DB >> 21858426

[Prophylaxis and therapy of the glucocorticoid-induced osteoporosis - a review of recent guidelines].

Bernhard Rintelen1, Klaus Bobacz, Günter Höfle, Peter Peichl, Franz Rainer, Kurt Weber, Markus Gaugg.   

Abstract

Several international guidelines for treatment and prophylaxis of glucocorticoid-induced osteoporosis (GIO) have been published. Consistent with the development of new therapeutic agents, a different approach to treatment can be recognized depending on the year of publication. Also, new insights for the postmenopausal osteoporosis leave their marks on recent guidelines. The working committee on Osteology of the Austrian Society for Rheumatology and Rehabilitation (ÖGR) sifted through actual guidelines and recent literature on the topic to develop recommendations for the prophylaxis and treatment of the GIO.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21858426     DOI: 10.1007/s00508-011-0042-8

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  34 in total

1.  EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.

Authors:  J N Hoes; J W G Jacobs; M Boers; D Boumpas; F Buttgereit; N Caeyers; E H Choy; M Cutolo; J A P Da Silva; G Esselens; L Guillevin; I Hafstrom; J R Kirwan; J Rovensky; A Russell; K G Saag; B Svensson; R Westhovens; H Zeidler; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2007-07-27       Impact factor: 19.103

Review 2.  Mechanisms of glucocorticoid-induced myopathy.

Authors:  O Schakman; H Gilson; J P Thissen
Journal:  J Endocrinol       Date:  2008-04       Impact factor: 4.286

3.  Recommendations for the registration of agents used in the prevention and treatment of glucocorticoid-induced osteoporosis.

Authors:  J E Compston; M Audran; B Avouac; G Bouvenot; J Devogelaer; R Eastell; F Fabris; C Gennari; E A Jones; J M Kaufman; E Lemmel; G Mazzuoli; D M Reid; J D Ringe; L Vanhaelst; R Ziegler; J Y Reginster
Journal:  Calcif Tissue Int       Date:  1996-11       Impact factor: 4.333

Review 4.  Use of oral corticosteroids and risk of fractures.

Authors:  T P Van Staa; H G Leufkens; L Abenhaim; B Zhang; C Cooper
Journal:  J Bone Miner Res       Date:  2000-06       Impact factor: 6.741

5.  High incidence rate of vertebral fractures during chronic prednisone treatment, in spite of bisphosphonate or alfacalcidol use. Extension of the alendronate or alfacalcidol in glucocorticoid-induced osteoporosis-trial.

Authors:  Jos N Hoes; Johannes W G Jacobs; Harry M J Hulsmans; Ron N J De Nijs; Willem F Lems; George A W Bruyn; Piet P M M Geusens; Johannes W J Bijlsma
Journal:  Clin Exp Rheumatol       Date:  2010-06-23       Impact factor: 4.473

Review 6.  Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis.

Authors:  J A Kanis; M Stevenson; E V McCloskey; S Davis; M Lloyd-Jones
Journal:  Health Technol Assess       Date:  2007-03       Impact factor: 4.014

7.  An assessment of bone mineral density in patients with Addison's disease and isolated ACTH deficiency treated with glucocorticoid.

Authors:  Naoko Chikada; Toshihiro Imaki; Mari Hotta; Kanji Sato; Kazue Takano
Journal:  Endocr J       Date:  2004-06       Impact factor: 2.349

Review 8.  Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates.

Authors:  D B Kimmel
Journal:  J Dent Res       Date:  2007-11       Impact factor: 6.116

9.  Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.

Authors:  S Aubrey Stoch; Kenneth G Saag; Maria Greenwald; Anthony I Sebba; Stanley Cohen; Nadia Verbruggen; Hilde Giezek; Joseph West; Thomas J Schnitzer
Journal:  J Rheumatol       Date:  2009-06-01       Impact factor: 4.666

Review 10.  Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis.

Authors:  Mark J Bolland; Alison Avenell; John A Baron; Andrew Grey; Graeme S MacLennan; Greg D Gamble; Ian R Reid
Journal:  BMJ       Date:  2010-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.